Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike
Apellis went gunning for Alexion’s star drug Soliris in a head-to-head PNH Phase III. And the smaller biotech said Tuesday morning that they came out with a clear win.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.